Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23313 | 0.91 | — | — | |
| SCHEMBL27907562 | 0.88 | — | — | |
| Ammonia Solution, Strong SCHEMBL4952162 | 0.88 | — | — | |
| Ethylene SCHEMBL27760243 | 0.88 | TP53 (0.35) | LMNAMAPTXBP1ATMSMN1; SMN2 | |
| Cyclohexane SCHEMBL65475 | 0.83 | LMNA (0.32) | LMNAMAPTXBP1ATMSMN1; SMN2 | |
| SCHEMBL11132396 | 0.83 | LMNA (0.32) | TSHRLMNAMAPTXBP1ATM | |
| Cyclopentane SCHEMBL4219993 | 0.83 | LMNA (0.32) | LMNAMAPTXBP1ATMSMN1; SMN2 | |
| SCHEMBL153454 | 0.83 | LMNA (0.32) | LMNAMAPTXBP1ATMSMN1; SMN2 | |
| SCHEMBL13388280 | 0.83 | LMNA (0.32) | LMNAMAPTXBP1ATMSMN1; SMN2 | |
| SCHEMBL924888 | 0.83 | LMNA (0.32) | LMNAMAPTXBP1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233935-A1 | Methods for Fabrication of Antimicrobial Surfaces | RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1945229-A2 | METHODS FOR FABRICATION OF ANTIMICROBIAL SURFACES | Research Foundation of the City University of New York (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008018890-A2 | METHODS FOR FABRICATION OF ANTIMICROBIAL SURFACES | RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233935-A1 | Methods for Fabrication of Antimicrobial Surfaces | ADH1A, ADH1C, HAO2 | TDP1 3634/4885TSHR 2444/4885LMNA 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.